ARCH Venture Partners Amends Beneficial Ownership in Neumora Therapeutics to 18.6%

This Amendment No. 4 to Schedule 13D, filed on April 1, 2026, reports an updated beneficial ownership stake in Neumora Therapeutics, Inc. (NMRA) by ARCH Venture Fund XII, L.P. and its affiliated entities. As of the event date on March 30, 2026, the reporting group collectively beneficially owns 33,847,838 shares of Common Stock, representing 18.6% of the class based on 182,040,945 shares outstanding. The holdings are distributed across several ARCH entities, including AVF VII, AVF VIII Overage, AVF X, AVF X Overage, and AVF XII. While the reporting persons have not effected any transactions in the Common Stock within the last 60 days, the amendment serves to update beneficial ownership details following the Issuer's most recent annual report. Individual reporting persons, including Managing Directors Robert Nelsen, Keith Crandell, and Kristina Burow, share voting and dispositive power over these shares due to their roles within the ARCH Venture Partners management structure. Kristina Burow also holds personal interests including vested options and restricted stock units.